Literature DB >> 9552852

Fast track admission for children with sickle cell crises. Should morphine or pethidine be given?

P Daggett.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9552852      PMCID： PMC1112823     

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  9 in total

1.  Toxicity of norpethidine in sickle cell crisis.

Authors:  B J Pryle; H Grech; P A Stoddart; R Carson; T O'Mahoney; F Reynolds
Journal:  BMJ       Date:  1992-06-06

Review 2.  Management of patients with sickle cell disease.

Authors:  S C Davies; L Oni
Journal:  BMJ       Date:  1997-09-13

3.  Evaluation of fast track admission policy for children with sickle cell crises: questionnaire survey of parents' preferences.

Authors:  C R Fertleman; A Gallagher; M A Rossiter
Journal:  BMJ       Date:  1997-09-13

Review 4.  Management of sickle pain.

Authors:  S K Ballas
Journal:  Curr Opin Hematol       Date:  1997-03       Impact factor: 3.284

5.  Ambulatory pediatrics.

Authors:  M Meates
Journal:  Arch Dis Child       Date:  1994-08       Impact factor: 3.791

6.  Pain, quality of life, and coping in sickle cell disease.

Authors:  P Fuggle; P A Shand; L J Gill; S C Davies
Journal:  Arch Dis Child       Date:  1996-09       Impact factor: 3.791

7.  Home management of sickle cell-related pain in children and adolescents: natural history and impact on school attendance.

Authors:  Barbara S Shapiro; David F Dinges; Emily Carota Orne; Nancy Bauer; Linnette B Reilly; Wayne G Whitehouse; Kwaku Ohene-Frempong; Martin T Orne
Journal:  Pain       Date:  1995-04       Impact factor: 6.961

8.  Survey of pain management therapy provided for children with sickle cell disease.

Authors:  C H Pegelow
Journal:  Clin Pediatr (Phila)       Date:  1992-04       Impact factor: 1.168

9.  Comparison of costs to the health sector of comprehensive and episodic health care for sickle cell disease patients.

Authors:  Y M Yang; A K Shah; M Watson; V N Mankad
Journal:  Public Health Rep       Date:  1995 Jan-Feb       Impact factor: 2.792
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.